Schizophrenia

  • Most Topular Stories

  • Top 5 Social Programs for People With...

    About.com Schizophrenia: Most Popular Articles
    24 Oct 2014 | 6:47 am
    Even in remission, people with schizophrenia usually have some degree of long-term disability from residual symptoms, and their ability to earn income is usually affected as well. The programs listed here exist to provide a safety net to help meet your basic needs for housing, food and medical care. This list provides links to official government websites for these programs, to help you learn if you're eligible and how to apply.
  • Unpacking the "Placebo Problem" in Antipsychotic Drug Trials

    Schizophrenia Research Forum: Research News
    20 Oct 2014 | 10:00 pm
    A large meta-analysis identifies factors to blame for the troubling increase in placebo response...
  • Could aspirin be a cure for schizophrenia?

    schizophrenic.com
    M Tyler
    23 Oct 2014 | 2:37 pm
    Common anti-inflammatory treatments, like aspirin, estrogen and Fluimucil may help to improve the efficacy of existing schizophrenia treatments, according to a new study presented at the European College of Neuropsychopharmacology (ECNP) in Berlin. The study included data on 26 double-blind, randomized control trials, providing evidence that schizophrenia symptoms were reduced in patients that took certain anti-inflammatory agents. "Inflammation and oxidative stress seem to be important factors in different mental disorders," said Celso Arango, commenting for the ECNP. "Patients with…
  • Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: An introduction to this Special Issue of schizophrenia research

    Schizophrenia Research
    Neal R. Swerdlow, Raquel E. Gur, David L. Braff
    22 Oct 2014 | 5:00 pm
    The COGS is a multi-site NIMH-sponsored investigation of the genetic basis of 12 primary and multiple secondary quantitative endophenotypes in schizophrenia.
  • Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2

    Schizophrenia Research
    Gregory A. Light, Neal R. Swerdlow, Michael L. Thomas, Monica E. Calkins, Michael F. Green, Tiffany A. Greenwood, Raquel E. Gur, Ruben C. Gur, Laura C. Lazzeroni, Keith H. Nuechterlein, Marlena Pela, Allen D. Radant, Larry J. Seidman, Richard F. Sharp, Larry J. Siever, Jeremy M. Silverman, Joyce Sprock, William S. Stone, Catherine A. Sugar, Debby W. Tsuang, Ming T. Tsuang, David L. Braff, Bruce I. Turetsky
    22 Oct 2014 | 5:00 pm
    Mismatch negativity (MMN) and P3a are auditory event-related potential (ERP) components that show robust deficits in schizophrenia (SZ) patients and exhibit qualities of endophenotypes, including substantial heritability, test–retest reliability, and trait-like stability. These measures also fulfill criteria for use as cognition and function-linked biomarkers in outcome studies, but have not yet been validated for use in large-scale multi-site clinical studies. This study tested the feasibility of adding MMN and P3a to the ongoing Consortium on the Genetics of Schizophrenia (COGS) study.
  • add this feed to my.Alltop

    Schizophrenia News

  • FDA Accepts New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia

    22 Oct 2014 | 12:41 pm
    The FDA has accepted for filing a new drug application for aripiprazole lauroxil , an investigational, once-monthly injectable atypical antipsychotic for the treatment of schizophrenia. Under the Prescription Drug User Fee Act , the FDA's target action date for the aripiprazole lauroxil NDA is August 22, 2015.
  • Ameritox and Ingenuity Health Expand Effort to Help Assess Medication ...

    21 Oct 2014 | 2:12 pm
    Ameritox , the nation's leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug risperidone ). This new method marks a critical step toward establishing a comprehensive reference database for commonly prescribed antipsychotic medications, providing behavioral health clinicians help in addressing the acute problem of medication non-adherence in those with serious mental illness.
  • Omeros Provides Update on PDE10 Inhibitor Program

    21 Oct 2014 | 6:31 am
    Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 inhibitor in development for the treatment of schizophrenia and Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition.
  • Aspirin, Anti-Inflammatory Medicine, Benefits Schizophrenia Treatment

    20 Oct 2014 | 11:48 am
    Anti-inflammatory medicines such as aspirin, estrogen, and Fluimucil can improve the efficacy of existing schizophrenia treatments, according to results announced at the European College of Neuropsychopharmacology conference in Berlin. Doctors have long believed that helping the immune system may benefit the treatment of schizophrenia, but until now there has been no conclusive evidence that this would be effective.
  • Aspirin shown to benefit schizophrenia treatment

    20 Oct 2014 | 7:55 am
    A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin.
 
  • add this feed to my.Alltop

    MedWorm: Schizophrenia

  • Basal ganglia anatomy and schizophrenia: the role of antipsychotic treatment.

    23 Oct 2014 | 5:08 pm
    Authors: Zampieri E, Bellani M, Crespo-Facorro B, Brambilla P Abstract Progressive enlargement of basal ganglia volume has been observed in schizophrenia individuals, potentially being sustained by chronic administration of antipsychotic drugs. Here we briefly summarise the state of the art of the role of antipsychotic in leading to increased basal ganglia in schizophrenia, particularly focusing on the caudate nucleus. PMID: 25335548 [PubMed - as supplied by publisher] (Source: Epidemiology and Psychiatric Sciences)MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this…
  • Serine Racemase Regulated by Binding to Stargazin and PSD-95 [Cell Biology]

    23 Oct 2014 | 4:00 pm
    In this study, we demonstrate that SR interacts with the synaptic proteins, postsynaptic density protein 95 (PSD-95) and stargazin, forming a ternary complex. SR binds to the PDZ3 domain of PSD-95 through the PDZ domain ligand at its C terminus. SR also binds to the C terminus of stargazin, which facilitates the cell membrane localization of SR and inhibits its activity. AMPA receptor activation internalizes SR and disrupts its interaction with stargazin, therefore derepressing SR activity, leading to more d-serine production and potentially facilitating NMDA receptor activation. These…
  • Well: Living With Schizophrenia: Coffee and Friends

    23 Oct 2014 | 10:33 am
    Getting to trust people well enough to call them a friend takes a lot of work. It’s especially hard when you are living with schizophrenia and think everyone is making fun of you. (Source: NYT)
  • Can the season of birth risk factor for schizophrenia be prevented by bright light treatment for the second trimester mother around the winter solstice?

    22 Oct 2014 | 4:00 pm
    The season of birth risk factor for schizophrenia exerts a pervasive effect on the global population, particularly at northerly latitudes. The winter infection hypothesis and the low vitamin D hypothesis are both compelling but lack conclusive clinical data. The present work develops a maternal-fetal chronobiological hypothesis for this season of birth risk factor and its prevention by maternal bright light treatment. Around the winter solstice, the chronobiological apparatus of the at-risk second trimester mother is characterized by a reduced maximum of her nocturnal plasma melatonin…
  • Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2

    22 Oct 2014 | 4:00 pm
    This study tested the feasibility of adding MMN and P3a to the ongoing Consortium on the Genetics of Schizophrenia (COGS) study. (Source: Schizophrenia Research)
 
  • add this feed to my.Alltop

    About.com Schizophrenia: What's Hot Now

  • What Do Hallucinations Feel Like in Schizophren...

    schizophrenia.guide@about.com
    24 Oct 2014 | 4:23 am
    Hallucinations are part of schizophrenia. This article focuses on what experiencing hallucinations feels like from a patient's perspective.
  • What Causes Schizophrenia?

    schizophrenia.guide@about.com
    24 Oct 2014 | 4:23 am
    There is some evidence that schizophrenia may be caused by an infectious disease interacting with an underlying genetic vulnerability.
  • The Difference between Schizophrenia and...

    schizophrenia.guide@about.com
    24 Oct 2014 | 4:23 am
    Schizophrenia and schizoaffective are two different disorders. This article discusses the relevant differences why that matters.
  • Schizophrenia Early Diagnosis

    schizophrenia.guide@about.com
    24 Oct 2014 | 4:23 am
    How early can schizophrenia be diagnosed? Are there warning signs that can guide prevention, early diagnosis and treatment?
  • Atypical Antipsychotic Drugs Used to Treat...

    schizophrenia.guide@about.com
    24 Oct 2014 | 4:23 am
    In the early 1990s a new class of drugs were developed to treat the psychotic symptoms of schizophrenia. These drugs, the atypical antipsychotics, have proven generally as effective as the antispychotics developed decades earlier, with fewer extrapyrimidal side effects. This list of the atypical antipsychotics provides links to drug safety information from the drug manufacturers' websites.
  • add this feed to my.Alltop

    About.com Schizophrenia: Most Popular Articles

  • Top 5 Social Programs for People With...

    24 Oct 2014 | 6:47 am
    Even in remission, people with schizophrenia usually have some degree of long-term disability from residual symptoms, and their ability to earn income is usually affected as well. The programs listed here exist to provide a safety net to help meet your basic needs for housing, food and medical care. This list provides links to official government websites for these programs, to help you learn if you're eligible and how to apply.
  • The Positive and Negative Symptoms of...

    24 Oct 2014 | 6:47 am
    Are you having experiences that seem unreal? Are you concerned about strange behavior in a loved one? Learn to understand and describe the symptoms of schizophrenia, so that you can communicate them to a doctor.
  • The mechanism of dopamine partial agonism in...

    24 Oct 2014 | 6:47 am
    How do antipsychotics work? What is partial dopamine antagonism and what role does it play in the treatment of schizophrenia?
  • How Schizophrenia Is Diagnosed

    24 Oct 2014 | 6:47 am
    The better you understand the language and the process of diagnosing schizophrenia, the better you can communicate with your doctor. Remember that only a psychologist or psychiatrist can rule out or diagnose schizophrenia.
  • Neurotransmitter

    24 Oct 2014 | 6:47 am
    Definition of the term, neurotransmitter
 
  • add this feed to my.Alltop

    Schizophrenia Bulletin - Advance Access

  • Multifactoriality in Psychiatric Disorders: A Computational Study of Schizophrenia

    Pavao, R., Tort, A. B. L., Amaral, O. B.
    20 Oct 2014 | 1:44 am
    The search for biological causes of mental disorders has up to now met with limited success, leading to growing dissatisfaction with diagnostic classifications. However, it is questionable whether most clinical syndromes should be expected to correspond to specific microscale brain alterations, as multiple low-level causes could lead to similar symptoms in different individuals. In order to evaluate the potential multifactoriality of alterations related to psychiatric illness, we performed a parametric exploration of published computational models of schizophrenia. By varying multiple…
  • Early Psychosis Intervention Services: A Work in Progress

    Dixon, L., Lieberman, J.
    20 Oct 2014 | 1:18 am
  • Identification of Rare, Single-Nucleotide Mutations in NDE1 and Their Contributions to Schizophrenia Susceptibility

    Kimura, H., Tsuboi, D., Wang, C., Kushima, I., Koide, T., Ikeda, M., Iwayama, Y., Toyota, T., Yamamoto, N., Kunimoto, S., Nakamura, Y., Yoshimi, A., Banno, M., Xing, J., Takasaki, Y., Yoshida, M., Aleksic, B., Uno, Y., Okada, T., Iidaka, T., Inada, T., Suzuki, M., Ujike, H., Kunugi, H., Kato, T., Yoshikawa, T., Iwata, N., Kaibuchi, K., Ozaki, N.
    20 Oct 2014 | 1:18 am
    Background: Nuclear distribution E homolog 1 (NDE1), located within chromosome 16p13.11, plays an essential role in microtubule organization, mitosis, and neuronal migration and has been suggested by several studies of rare copy number variants to be a promising schizophrenia (SCZ) candidate gene. Recently, increasing attention has been paid to rare single-nucleotide variants (SNVs) discovered by deep sequencing of candidate genes, because such SNVs may have large effect sizes and their functional analysis may clarify etiopathology. Methods and Results: We conducted mutation screening of NDE1…
  • Implications for Services and Policy

    Goldman, H., Hogan, M.
    18 Oct 2014 | 1:15 am
  • Methodological Comments: McFarlane et al

    Kraemer, H. C.
    16 Oct 2014 | 5:40 am
    Does the McFarlane et al study1 provide a model for practical trials? Unfortunately, not. The methodological problems are here reviewed and used as a springboard to set out methodological criteria that might define such a model.
  • add this feed to my.Alltop

    Schizophrenia Research

  • Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: An introduction to this Special Issue of schizophrenia research

    Neal R. Swerdlow, Raquel E. Gur, David L. Braff
    22 Oct 2014 | 5:00 pm
    The COGS is a multi-site NIMH-sponsored investigation of the genetic basis of 12 primary and multiple secondary quantitative endophenotypes in schizophrenia.
  • Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2

    Gregory A. Light, Neal R. Swerdlow, Michael L. Thomas, Monica E. Calkins, Michael F. Green, Tiffany A. Greenwood, Raquel E. Gur, Ruben C. Gur, Laura C. Lazzeroni, Keith H. Nuechterlein, Marlena Pela, Allen D. Radant, Larry J. Seidman, Richard F. Sharp, Larry J. Siever, Jeremy M. Silverman, Joyce Sprock, William S. Stone, Catherine A. Sugar, Debby W. Tsuang, Ming T. Tsuang, David L. Braff, Bruce I. Turetsky
    22 Oct 2014 | 5:00 pm
    Mismatch negativity (MMN) and P3a are auditory event-related potential (ERP) components that show robust deficits in schizophrenia (SZ) patients and exhibit qualities of endophenotypes, including substantial heritability, test–retest reliability, and trait-like stability. These measures also fulfill criteria for use as cognition and function-linked biomarkers in outcome studies, but have not yet been validated for use in large-scale multi-site clinical studies. This study tested the feasibility of adding MMN and P3a to the ongoing Consortium on the Genetics of Schizophrenia (COGS) study.
  • Psychotic-like experiences in pregnant and postpartum women without a history of psychosis

    Aisling Mannion, Pauline Slade
    21 Oct 2014 | 5:00 pm
    This study investigated whether psychotic-like experiences (PLEs) are prevalent amongst women in pregnancy and/or in the early postnatal phase, and whether the predictors identified in the literature for non-puerperal psychosis apply in a general sample of perinatal women.
  • Myelin, myelin-related disorders, and psychosis

    Michelle I. Mighdoll, Ran Tao, Joel E. Kleinman, Thomas M. Hyde
    21 Oct 2014 | 5:00 pm
    The neuropathological basis of schizophrenia and related psychoses remains elusive despite intensive scientific investigation. Symptoms of psychosis have been reported in a number of conditions where normal myelin development is interrupted. The nature, location, and timing of white matter pathology seem to be key factors in the development of psychosis, especially during the critical adolescent period of association area myelination. Numerous lines of evidence implicate myelin and oligodendrocyte function as critical processes that could affect neuronal connectivity, which has been…
  • An incongruent reality: The N400 in relation to psychosis and recovery

    Felicia Jackson, Dan Foti, Roman Kotov, Greg Perlman, Daniel H. Mathalon, Greg Hajcak Proudfit
    21 Oct 2014 | 5:00 pm
    Cognitive impairments and delusions are hallmarks of schizophrenia, and are thought to be due in part to abnormalities in semantic priming. The N400, a neural measure of semantic processing, is found to be reduced in schizophrenia. However, it is unclear if individuals with other psychoses (e.g., mood disorders or substance abuse with psychotic features) also show this impairment, and whether N400 reduction relates to real-world functioning and recovery.
  • add this feed to my.Alltop

    Schizophrenia Research

  • Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2

    Gregory A. Light, Neal R. Swerdlow, Michael L. Thomas, Monica E. Calkins, Michael F. Green, Tiffany A. Greenwood, Raquel E. Gur, Ruben C. Gur, Laura C. Lazzeroni, Keith H. Nuechterlein, Marlena Pela, Allen D. Radant, Larry J. Seidman, Richard F. Sharp, Larry J. Siever, Jeremy M. Silverman, Joyce Sprock, William S. Stone, Catherine A. Sugar, Debby W. Tsuang, Ming T. Tsuang, David L. Braff, Bruce I. Turetsky
    22 Oct 2014 | 5:00 pm
    Mismatch negativity (MMN) and P3a are auditory event-related potential (ERP) components that show robust deficits in schizophrenia (SZ) patients and exhibit qualities of endophenotypes, including substantial heritability, test–retest reliability, and trait-like stability. These measures also fulfill criteria for use as cognition and function-linked biomarkers in outcome studies, but have not yet been validated for use in large-scale multi-site clinical studies. This study tested the feasibility of adding MMN and P3a to the ongoing Consortium on the Genetics of Schizophrenia (COGS) study.
  • Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: An introduction to this Special Issue of schizophrenia research

    Neal R. Swerdlow, Raquel E. Gur, David L. Braff
    22 Oct 2014 | 5:00 pm
    The COGS is a multi-site NIMH-sponsored investigation of the genetic basis of 12 primary and multiple secondary quantitative endophenotypes in schizophrenia.
  • Myelin, myelin-related disorders, and psychosis

    Michelle I. Mighdoll, Ran Tao, Joel E. Kleinman, Thomas M. Hyde
    21 Oct 2014 | 5:00 pm
    The neuropathological basis of schizophrenia and related psychoses remains elusive despite intensive scientific investigation. Symptoms of psychosis have been reported in a number of conditions where normal myelin development is interrupted. The nature, location, and timing of white matter pathology seem to be key factors in the development of psychosis, especially during the critical adolescent period of association area myelination. Numerous lines of evidence implicate myelin and oligodendrocyte function as critical processes that could affect neuronal connectivity, which has been…
  • Psychotic-like experiences in pregnant and postpartum women without a history of psychosis

    Aisling Mannion, Pauline Slade
    21 Oct 2014 | 5:00 pm
    This study investigated whether psychotic-like experiences (PLEs) are prevalent amongst women in pregnancy and/or in the early postnatal phase, and whether the predictors identified in the literature for non-puerperal psychosis apply in a general sample of perinatal women.
  • An incongruent reality: The N400 in relation to psychosis and recovery

    Felicia Jackson, Dan Foti, Roman Kotov, Greg Perlman, Daniel H. Mathalon, Greg Hajcak Proudfit
    21 Oct 2014 | 5:00 pm
    Cognitive impairments and delusions are hallmarks of schizophrenia, and are thought to be due in part to abnormalities in semantic priming. The N400, a neural measure of semantic processing, is found to be reduced in schizophrenia. However, it is unclear if individuals with other psychoses (e.g., mood disorders or substance abuse with psychotic features) also show this impairment, and whether N400 reduction relates to real-world functioning and recovery.
 
  • add this feed to my.Alltop

    Schizophrenia News -- ScienceDaily

  • Aspirin shown to benefit schizophrenia treatment

    20 Oct 2014 | 6:01 am
    Some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments, new research suggests. Research has shown that the immune system is linked to certain psychiatric disorders, such as schizophrenia and bipolar disorder. Research has shown that "antioxidants and anti-inflammatory drugs could not only reduce symptoms associated with the disorders but also prevent the appearance of neurobiological abnormalities and transition to psychosis if given early during brain development," experts say.
  • YouTube as peer support for severe mental illness

    17 Oct 2014 | 3:37 pm
    People with severe mental illness such as schizophrenia, schizoaffective disorder or bipolar disorder use a popular social media website like YouTube to provide and receive naturally occurring peer support, researchers report.
  • Increased health risks linked to first-episode psychosis

    8 Oct 2014 | 5:39 pm
    Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness. Patients with schizophrenia are already known to have higher rates of premature death than the general population. Elevated risks of heart disease and metabolic issues such as high blood sugar in people with first episode psychosis are due to an interaction of mental illness, unhealthy lifestyle behaviors and antipsychotic medications that may accelerate these risks, experts say.
  • Working memory hinders learning in schizophrenia

    7 Oct 2014 | 3:42 pm
    Trouble with working memory makes a distinct contribution to the difficulty people with schizophrenia sometimes have in learning, according to a new study. The researchers employed a specially designed experiment and computational models to distinguish the roles of working memory and reinforcement learning.
  • Schizophrenia, bipolar disorder associated with dendritic spine loss in brain

    2 Oct 2014 | 6:24 am
    Schizophrenia and bipolar disorder both appear to be associated with dendritic spine loss in the brain, suggesting the two distinct disorders may share common pathophysiological features.
  • add this feed to my.Alltop

    Schizophrenia Society of Nova Scotia

  • The Schizophrenia Society of Nova Scotia's 26th Annual Conference - The Brain: Mental Health & Psychiatric Disorders

    24 Oct 2014 | 4:30 am
    Friday, November 7th, 20149:00 am to 3:45 pmMcInnes RoomStudent Union Building, Dalhousie University6136 University AvenueHalifax, Nova ScotiaKeynote Speaker"Brain Stimulation in Resistant Depression"Dr. Z. Jeff DaskalakisProfessor of PsychiatryDepartment of PsychiatryUniversity of TorontoandDirectorTemerty Centre for Therapeutic Brain InterventionCentre for Addiction and Mental HealthToronto, Ontario To download Dr. Daskalakis' biosketch (PDF), please click here.Invited Speakers"Early Intervention for Psychotic Disorders - Recent Findings"Dr. Sabina AbidiInterim Associate ChiefDivision of…
  • The "From Recovery to Discovery" Mental Health Peer Support Group-Halifax

    24 Oct 2014 | 4:00 am
    This Thursday, October 30th, 6:30 pmMeetingsEvery Thursday Evening6:30 pm to 8:30 pmCommunity RoomAtlantic Superstore – Barrington Street 1075 Barrington StreetHalifax, Nova Scotia Plenty of free parking!The Atlantic Superstore – Barrington Street is on the 3, 7, 9, and 41 Metro Transit bus routes.The From Recovery to Discovery Mental Health Peer Support Group is open to anyone affected by any type of mental illness, and this includes family members and friends.Free! Thursday, October 30th, 2014, 6:30 pm to 8:30 pmMusic, Poetry, and Mental HealthandA Halloween Party Everyone…
  • The Kings County Chapter of the SSNS presents "A Beautiful Mind"

    24 Oct 2014 | 3:30 am
    Wednesday, November 5th, 7:00 pmKentville, Nova ScotiaPlease click on the image to magnify it.Also see:Kings County Chapter of the Schizophrenia Society of Nova Scotia
  • Of Sound Faith - A peer-led initiative encouraging the healing and recovery of those with experiences in mental illness

    24 Oct 2014 | 3:00 am
    Begins in Halifax Regional Municipality in November 2014For further information or to register, please contact Lesley-Ann Kean, Project Coordinator, Of Sound Faith, by sending an email to ofsoundfaith@live.ca.Please click on the image to magnify it.To download the PDF version of the above flyer, please click here.Of Sound Faith is a project funded through a 2014-2015 Consumer-Led Initiative Grant from the Nova Scotia Department of Health and Wellness.
  • Getting Mental Health Crisis Support in Nova Scotia

    21 Oct 2014 | 3:30 am
    Call (902) 429-8167 or 1-888-429-8167 (toll free)The Mental Health Mobile Crisis Team (MHMCT) provides intervention and short term crisis management for children, youth and adults experiencing a mental health crisis. They offer 24/7 telephone intervention throughout Nova Scotia - (902) 429-8167 or 1-888-429-8167 (toll free) - and mobile response (1:00 pm to 1:00 am) in areas served by Halifax Regional Police including Halifax, Dartmouth and Bedford.Note that this video is two years old and it does not mention the 24/7 telephone crisis intervention service that is now available throughout Nova…
 
  • add this feed to my.Alltop

    schizophrenic.com

  • Could aspirin be a cure for schizophrenia?

    M Tyler
    23 Oct 2014 | 2:37 pm
    Common anti-inflammatory treatments, like aspirin, estrogen and Fluimucil may help to improve the efficacy of existing schizophrenia treatments, according to a new study presented at the European College of Neuropsychopharmacology (ECNP) in Berlin. The study included data on 26 double-blind, randomized control trials, providing evidence that schizophrenia symptoms were reduced in patients that took certain anti-inflammatory agents. "Inflammation and oxidative stress seem to be important factors in different mental disorders," said Celso Arango, commenting for the ECNP. "Patients with…
  • Men and women at risk for psychosis experience different emotions and symptoms

    M Tyler
    16 Oct 2014 | 2:14 pm
    The subjective experiences of individuals at risk for psychosis differ depending on gender, reports a new study published in Psychiatric Services in Advance. Women seem to be more concerned with past traumas and a family history of psychosis, while men describe feeling alienated and in need of social connection. For the study, researchers conducted interviews with 27 participants who had a significant clinical risk for psychosis. By understanding how both genders cope with their experiences, intervention approaches can better prevent the onset of symptoms or manage the condition in…
  • Higher drug doses needed for pregnant women with psychosis, study finds

    M Tyler
    14 Oct 2014 | 10:08 am
    Pregnant women with psychosis may need higher doses of antipsychotic drugs, or neuroleptics, in order to maintain the drugs' therapeutic effects, a new study reports. Current drugs have been deemed much more safe for pregnant women in terms of side effects, but physicians often reduce dosage anyway. Yet a reduced dosage may put both the mother and unborn child at risk for harm, as untreated symptoms of psychosis can lead to alcohol or drug abuse, increased risk of suicide and relapse of other psychotic symptoms. The therapeutic range For the study, researchers measured levels of aripiprazole…
  • Patients with psychosis have increased risk of potentially fatal health risks

    M Tyler
    10 Oct 2014 | 8:38 am
    Higher risk of heart disease or metabolic syndrome in people with first-episode psychosis can be traced back to the complications of mental illness, reports a new study published in JAMA Psychiatry. The study is one of the fist to reveal results from the National Institute of Mental Health's Recovery After an Initial Schizophrenia Episode (RAISE) project, which examines cases of first-episode psychosis and corresponding treatment results in community settings. The average age of the nearly 400 individuals who were part of the study was only 24 years old, suggesting that patients need early…
  • Problems with working memory makes learning difficult for schizophrenics

    M Tyler
    8 Oct 2014 | 11:45 am
    Learning might be more of challenge for people with schizophrenia based on poorer working memory, according to Brown researchers. In a learning task where patients - 49 with schizophrenia and 36 healthy controls - were shown a set of images that corresponded to particular buttons that needed to be pushed, subjects with schizophrenia had a much harder time recalling which button to push, especially when the researchers increased the amount of images and buttons. With good working memory, the researchers explained, a typical person wouldn't need to see an image more than a few times to remember…
  • add this feed to my.Alltop

    Schiz Life

  • Mental Health Laws: Schizophrenia Advocacy

    Schiz Life
    5 Oct 2014 | 12:55 pm
    Twenty to 25% of the homeless populace in the United States have a serious mental illness, including schizophrenia, those with manic outbreaks, and those with severe depressive episodes. The mental health and legal systems are significantly failing these 9.6 million people creating a critical deficiency of services, such as community-based treatment, psychiatric prescriptions, and living accommodations. As a result, police are typically called to deal with incidents or disruptions triggered by the behavior of someone suffering with a serious mental disorder. Jails are the contemporary mental…
  • Is Schizophrenia 8 Distinct Disorders?

    Schiz Life
    18 Sep 2014 | 9:01 am
    We have all likely pondered over the many various types of schizophrenia and the wide range of symptoms that can manifest and realized how different some of them are.  It seems like we might be dealing with several distinct disorders from a surface viewpoint.  There has been little support for this concept “under the hood” when considering neurological and genetic factors, until now. “Multiple Genetically Distinct Disorders” Researchers at the Washington University School of Medicine reported some intriguing results in the American Journal of Psychiatry on the 15th…
  • Amy’s Story: Living with Schizophrenia

    Schiz Life
    6 Sep 2014 | 4:45 pm
    The following is a post by our friend Amy Kay, who has begun, recently and courageously, to voice and share her experiences with schizophrenia on her blog Voice of a Schizophrenic.  We are happy to share her story.. I used to tell people “I have a bad brain.” I am not going to say I suffer from schizophrenia but rather I endure and cope with it. My name is Amy Kay and I have schizophrenia. I do not want to hurt others or myself. Neither do I hear voices and I no longer live in a delusional world. In 2008 during my initial psychiatric breakdown it started with a state of euphoria.
  • New Schizophrenia Dimmer Switch Medication Concept

    Schiz Life
    12 Aug 2014 | 12:51 pm
    As we all know, schizophrenia medication can cause a rash of ill effects in it’s users, often times to the point that the disruption from the medication is subjectively worse than the symptoms of the illness they are meant to treat.  Finding the right balance of medications to properly treat the problem without creating addition side effects can be a long and drawn out process that is frustrating to the patient and the doctor.  However, a breakthrough in this process may have just occurred… Yesterday, the Monash University in Melbourne, Australia published its findings (read the…
  • The 12 Core Functions: Your Therapist and Treatment Path

    Schiz Life
    20 Jul 2014 | 5:43 am
    The 12 Core Functions: Your Therapist and Treatment Path A sad reality is that many people dealing with the symptoms of schizophrenia simply fail to receive treatment.  There are lots of various reasons why this can happen, but one of the reasons is a resistance and fear in not understanding how treatment will transpire.  This article is meant to give the reader a general overview of what the therapist is thinking and the guidelines they follow to perform their task.  Your treatment will be personalized and tailored specifically to your experiences, symptoms, and receptiveness, but it will…
Log in